Calling the company’s efforts to notify customers about its recall of breathing machines “inadequate,” the US Food and Drug Administration on 10 March sent a letter to Philips Respironics that orders the manufacturer to beef up its recall communications, among other directives.
Philips in June 2021 recalled millions of bi-level positive airway pressure (BiPAP), continuous positive airway pressure (CPAP), and other mechanical...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?